Release Summary

Calistoga Pharmaceuticals announced start of a Phase 1 combination trial of CAL-101 with Rituxan® and/or Treanda® in patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia.

Calistoga Pharmaceuticals, Inc.